Chapter 11
Therapeutic Angiogenesis
K. Craig Kent,
K. Craig Kent
Search for more papers by this authorK. Craig Kent,
K. Craig Kent
Search for more papers by this authorBook Editor(s):Enrico Ascher,
L. H. Hollier,
D. Eugene Strandness,
Jonathan B. Towne,
Keith Calligaro,
K. Craig Kent,
Gregory L. Moneta,
William H. Pearce,
John J. Ricotta,
Henry Haimovici,
Enrico Ascher
Search for more papers by this authorL. H. Hollier
Search for more papers by this authorD. Eugene Strandness
Search for more papers by this authorJonathan B. Towne
Search for more papers by this authorKeith Calligaro
Search for more papers by this authorK. Craig Kent
Search for more papers by this authorGregory L. Moneta
Search for more papers by this authorWilliam H. Pearce
Search for more papers by this authorJohn J. Ricotta
Search for more papers by this authorHenry Haimovici
Search for more papers by this authorFirst published: 01 January 2004
Summary
This chapter contains section titled:
-
Angiogenic Protein
-
Mechanisms of Drug Delivery
-
Potential Side Effects
-
Clinical Trials
-
New Horizons
-
Summary
-
Thrombogenesis
References
- Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. trends Biochem Sci 1997; 22: 251–256.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.
- Semenza GL. Hypoxia inducible factor 1: master regulator of oxygen homeostasis. Curr Opin Genet Dev 1999; 8: 588–594.
- Shyy JY, Hsieh HJ, et al. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 expression in vascular endothelium. Proc Natl Acad Sci 1994; 91: 4678–4682.
- Chappell DC, Varner SE, et al. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 1998; 82: 532–539.
- Ito WD, Arras M, et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997; 80: 829–837.
- Wolf C, Cai WJ, et al. Vascular remodeling and altered protein expression during growth of coronary collateral arteries. J Mol Cell Cardiol 1998; 30: 2291–2305.
- Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161 (2): 851–858.
- Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999; 237: 1–30.
- Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999; 237: 59–83.
- Levy AP, Levy NS, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270 (22): 13333–13340.
- Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001; 107 (1): 1–3.
- Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995; 59 (3): 423–450.
- Paulding WR, Czyzyk-Krzeska MF. Hypoxia-induced regulation of mRNA stability. Adv Exp Med Biol 2000; 475: 111–121.
- Brogi E, Schatteman G, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996; 97 (2): 469–476.
- Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22 (4): 201–207.
- Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophy Acta 1992; 1135: 185–199.
- Szebenyi G, Fallon JF. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol 1999; 185: 45–106.
- Unger EF GL, Epstein SE, et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000; 85 (12): 1414–1419.
- Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 1996; 119: 591–600.
- Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun 1997; 239: 639–644.
- Nabel EG, Nabel GJ. Complex models for the study of gene function in cardiovascular biology. Annu Rev Physiol 1994; 56: 741–761.
- Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996; 334 (18): 1185–1187.
- Zabner J, Petersen DM, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75–83.
- Wolff JA, Malone RW, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–1468.
- Lin H, Parmacek MS, et al. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 1990; 82: 2217–2221.
- Hedin U, Wahlberg E. Gene therapy and vascular disease: Potential applications in vascular surgery. Eur J Vasc Endovasc Surg 1997; 13: 101–111.
- Isner JM, Baumgartner I, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results. J Vasc Surg 1998; 28: 964–973.
- Tsurumi Y, Takeshita S, et al. Direct intramucular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94: 3281–3290.
- Banai S, Jaklitsch MT, et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991; 69 (1): 76–85.
- Baumgartner I, Pieczek A, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97 (12): 1114–1123.
- Rauh G, Gravereaux E, et al. Asessment of safety and efficacy of intramuscular gene therapy VEGF-2 in patients with critical limb ischemia (abstract). Circulation 1999; 100: 1–770.
- Makinen K, Manninen H, et al. VEGF gene transfer to human lower limb artery: a placebo-controlled, randomized, double-blinded phase II study (abstract). Circulation 2001; 104: 253.
- Lazarous DF, Unger EF, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 2000; 36 (4): 1239–1244.
- Comerota AJ, Throm RC, et al. Plasmid-linked naked DNA (NV1FGF) for the treatment of end-stage unrecon-structible lower extremity ischemia: preliminary results of a phase. 49th Scientific Program, Am Assoc Vasc Surg. Baltimore, MD; 2001.
- Asahara T, Murohara T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964–967.
- Asahara T, Masuda H, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vascu-logenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221–228.
- Iwaguro H, Yamaguchi J, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105: 732–738.
